Xuanzhu Biotechnology: The new indication of Annilat Sodium has been approved to conduct Phase III clinical trials.

Xuanzhu Bioscience announcement, the company's independently developed innovative drug Anailazol sodium enteric-coated tablets have been approved by the China National Medical Products Administration Drug Evaluation Center, and a Phase III clinical study of bismuth quadruple therapy containing Anailazol sodium enteric-coated tablets for eradicating Helicobacter pylori will be conducted. The study plans to include 556 Helicobacter pylori-positive adult subjects, with the primary endpoint being the eradication rate of Helicobacter pylori confirmed by the 13C-urea breath test on the 28th day after the end of treatment.